<p>隨着 2026 年的到來，亞洲市場呈現出不同的動能，中國的製造業部門顯示出復甦的跡象，而韓國的出口達到了創紀錄的高點。在這個動態的環境中，識別高增長的科技股票需要尋找能夠利用區域經濟趨勢和技術進步來推動創新並佔據市場份額的公司。</p>
<h3>亞洲十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>巨人網絡集團</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中際旭創</td>
<td>36.62%</td>
<td>38.27%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>福斯泰克</td>
<td>37.25%</td>
<td>52.10%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金迴路電子</td>
<td>31.06%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>生益電子</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>知商</td>
<td>35.50%</td>
<td>33.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>生益科技有限公司</td>
<td>21.94%</td>
<td>32.84%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLL 有限公司</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科技發展</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科濟藥業-B</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲高增長科技和人工智能股票篩選器的 186 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>醫渡科技 (SEHK:2158)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 醫渡科技是一家投資控股公司，提供利用大數據和人工智能技術的醫療解決方案，業務覆蓋中國等多個國家，市值為 60.3 億港元。</p>
<p><strong>運營：</strong> 醫渡科技通過三個主要業務部門產生收入：生命科學解決方案（2.4075 億人民幣）、大數據平台和解決方案（3.654 億人民幣）以及健康管理平台和解決方案（1.3749 億人民幣）。該公司利用大數據和人工智能技術在中國、文萊和新加坡等多個國家提供醫療解決方案。</p>
<p>醫渡科技作為亞洲高增長科技領域的一員，展現出韌性和顯著增長潛力。報告顯示，銷售額同比增長至 3.5811 億人民幣，較上年的 3.2945 億人民幣有所增加，淨虧損大幅減少至 1460 萬人民幣，較上年的 4345 萬人民幣有所改善，顯示出良好的財務復甦趨勢。儘管目前尚未盈利，醫渡的收入預計將以 17.7% 的年增長率增長，超過香港市場平均 8.4% 的增速。此外，盈利預計將以 94.18% 的年增長率激增，使醫渡在未來三年內有望實現盈利，儘管目前在競爭激烈的醫療服務領域表現平平，預測的股本回報率僅為 1.9%。</p>
<ul>
<li>在這裏深入瞭解醫渡科技的具體情況，查看我們的詳細健康報告。</li>
<li>通過查看我們的歷史業績報告，獲取醫渡科技的歷史表現洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c787a8e8-cf73-4138-a828-dd7fdee4d0e9/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c787a8e8-cf73-4138-a828-dd7fdee4d0e9/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 1 月的 SEHK:2158 收入和支出明細</p>
<h2>甘李藥業 (SHSE:603087)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 甘李藥業是一家生物製藥公司，專注於胰島素類似物活性藥物成分（API）和注射劑的研究、開發、生產和銷售，市值約為 425.5 億人民幣。</p>
<p><strong>運營：</strong> 甘李藥業的收入主要來自胰島素及相關產品的開發、生產和銷售，金額為 38.5 億人民幣。該公司的運營專注於中國的生物製藥領域。</p>
<p>在強勁的亞洲科技環境中，甘李藥業在創新糖尿病治療方面取得了顯著進展。公司最近宣佈與 Lupin 簽署許可協議，推出 Bofanglutide，可能成為首個每兩週一次的 GLP-1 受體激動劑，有望改變肥胖和糖尿病管理。這一消息緊隨其胰島素甘精胰島素獲得 EMA 的生物類似藥認證，突顯了甘李藥業在慢性病護理領域擴展全球足跡的承諾。甘李藥業的收入同比增長 35.8%，盈利增長 61.3%，不僅超越了區域增長率，還鞏固了其在未來醫療解決方案中的角色。</p>
<ul>
<li>在這裏深入瞭解甘李藥業的完整分析健康報告。</li>
<li>查看我們的歷史業績報告，以獲取甘李藥業的過去表現洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 1 月的 SHSE:603087 收入和支出明細</p>
<h2>迅博科技 (TWSE:2345)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 迅博科技股份有限公司從事計算機網絡系統及無線局域網硬件和軟件產品的開發、製造和銷售，業務覆蓋台灣、美國、亞太地區、歐洲及其他國際市場，市值為 6734.8 億新台幣。</p>
<p><strong>運營：</strong> 迅博科技的主要收入來源於其計算機網絡部門，收入為 2152.7 億新台幣。該公司在台灣、美國和歐洲等多個地區運營。</p>
<p>Accton Technology 最近與 Edgecore Networks、1Finity 和 Liqid 建立的戰略聯盟，旨在開發尖端的數據中心解決方案，突顯了其在亞洲科技領域的創新優勢。此次合作旨在增強長距離光子網絡連接，這對現代數據中心的高傳輸速率和低延遲至關重要。在財務方面，Accton 的第三季度收入從去年同期的 281.9 億新台幣飆升至 729.5 億新台幣，淨收入則增長至 78.3 億新台幣，增長了三倍。這些數據反映出年化收入增長率為 24.1%，盈利增長率為 24.9%，使 Accton 在高需求科技領域的未來擴展中處於良好位置。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Accton Technology 的動態。</li>
<li>瞭解 Accton Technology 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a35f34df-42b2-4cae-940c-cc2a6dd214f4/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a35f34df-42b2-4cae-940c-cc2a6dd214f4/chart/revenue-and-expenses-breakdown"/></p>
<p>TWSE:2345 截至 2026 年 1 月的收入和支出明細</p>
<h2>總結</h2>
<ul>
<li>點擊瀏覽其餘 183 家亞洲高增長科技和人工智能股票。</li>
<li>擁有這些公司的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>免費使用 Simply Wall St 的應用程序簡化您的投資策略，並受益於對全球各地股票的廣泛研究。</li>
</ul>
<h2>對其他選擇感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過分析師和管理層的樂觀展望，為您的投資組合注入強勁增長潛力的公司。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

科濟藥業-B

醫渡科技

中際旭創

<p>隨着 2026 年的開始，亞洲市場展現出不同的動能，中國的製造業正在復甦，而韓國的出口達到了創紀錄的高點。關鍵的高增長科技股票包括巨人網絡集團、中際旭創和科濟藥業-B 等。醫渡科技和幹李藥業因其創新的醫療解決方案和顯著的收入增長而備受矚目。艾克頓科技因其在網絡系統和戰略聯盟方面的進展而受到認可。總體而言，亞洲科技領域正處於增長的有利位置，受到經濟趨勢和技術進步的推動</p>

<p>As 2026 begins, Asian markets are experiencing varied momentum, with China's manufacturing sector showing signs of recovery and South Korea's exports reaching record highs. In this dynamic environment, identifying high growth tech stocks involves looking for companies that can leverage regional economic trends and technological advancements to drive innovation and capture market share.</p>
<div class="lb-trans"><p>隨着 2026 年的到來，亞洲市場呈現出不同的動能，中國的製造業部門顯示出復甦的跡象，而韓國的出口達到了創紀錄的高點。在這個動態的環境中，識別高增長的科技股票需要尋找能夠利用區域經濟趨勢和技術進步來推動創新並佔據市場份額的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In Asia</h3>
<div class="lb-trans"><h3>亞洲十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giant Network Group</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>36.62%</td>
<td>38.27%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>37.25%</td>
<td>52.10%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>31.06%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Knowmerce</td>
<td>35.50%</td>
<td>33.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>21.94%</td>
<td>32.84%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>巨人網絡集團</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中際旭創</td>
<td>36.62%</td>
<td>38.27%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>福斯泰克</td>
<td>37.25%</td>
<td>52.10%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金迴路電子</td>
<td>31.06%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>生益電子</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>知商</td>
<td>35.50%</td>
<td>33.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>生益科技有限公司</td>
<td>21.94%</td>
<td>32.84%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLL 有限公司</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科技發展</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科濟藥業-B</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 186 stocks from our Asian High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲高增長科技和人工智能股票篩選器的 186 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Yidu Tech (SEHK:2158)</h2>
<div class="lb-trans"><h2>醫渡科技 (SEHK:2158)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Yidu Tech Inc. is an investment holding company that offers healthcare solutions leveraging big data and artificial intelligence technologies in various countries, including China, with a market cap of HK$6.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 醫渡科技是一家投資控股公司，提供利用大數據和人工智能技術的醫療解決方案，業務覆蓋中國等多個國家，市值為 60.3 億港元。</p>
</div><p><strong>Operations:</strong> Yidu Tech generates revenue through three main segments: Life Sciences Solutions (CN¥240.75 million), Big Data Platform and Solutions (CN¥365.40 million), and Health Management Platform and Solutions (CN¥137.49 million). The company leverages big data and AI technologies to provide healthcare solutions across multiple countries, including China, Brunei, and Singapore.</p>
<div class="lb-trans"><p><strong>運營：</strong> 醫渡科技通過三個主要業務部門產生收入：生命科學解決方案（2.4075 億人民幣）、大數據平台和解決方案（3.654 億人民幣）以及健康管理平台和解決方案（1.3749 億人民幣）。該公司利用大數據和人工智能技術在中國、文萊和新加坡等多個國家提供醫療解決方案。</p>
</div><p>Yidu Tech, a player in the high-growth tech sector in Asia, has demonstrated resilience and potential for significant growth. With a reported sales increase to CNY 358.11 million from CNY 329.45 million year-over-year and a substantial reduction in net loss to CNY 14.6 million from CNY 43.45 million, the company shows promising financial recovery trends. Despite current unprofitability, Yidu's revenue is projected to grow at an annual rate of 17.7%, outpacing the Hong Kong market's average of 8.4%. Moreover, earnings are expected to surge by an impressive 94.18% annually, positioning Yidu favorably for future profitability within three years as it navigates through the competitive healthcare services landscape where it currently underperforms with a modest forecasted return on equity of only 1.9%.</p>
<div class="lb-trans"><p>醫渡科技作為亞洲高增長科技領域的一員，展現出韌性和顯著增長潛力。報告顯示，銷售額同比增長至 3.5811 億人民幣，較上年的 3.2945 億人民幣有所增加，淨虧損大幅減少至 1460 萬人民幣，較上年的 4345 萬人民幣有所改善，顯示出良好的財務復甦趨勢。儘管目前尚未盈利，醫渡的收入預計將以 17.7% 的年增長率增長，超過香港市場平均 8.4% 的增速。此外，盈利預計將以 94.18% 的年增長率激增，使醫渡在未來三年內有望實現盈利，儘管目前在競爭激烈的醫療服務領域表現平平，預測的股本回報率僅為 1.9%。</p>
</div><ul>
<li>Dive into the specifics of Yidu Tech here with our thorough health report.</li>
<li>Gain insights into Yidu Tech's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解醫渡科技的具體情況，查看我們的詳細健康報告。</li>
<li>通過查看我們的歷史業績報告，獲取醫渡科技的歷史表現洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c787a8e8-cf73-4138-a828-dd7fdee4d0e9/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/c787a8e8-cf73-4138-a828-dd7fdee4d0e9/chart/revenue-and-expenses-breakdown"/></p>
<p>SEHK:2158 Revenue and Expenses Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 SEHK:2158 收入和支出明細</p>
</div><h2>Gan &amp; Lee Pharmaceuticals (SHSE:603087)</h2>
<div class="lb-trans"><h2>甘李藥業 (SHSE:603087)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Gan &amp; Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China with a market capitalization of approximately CN¥42.55 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 甘李藥業是一家生物製藥公司，專注於胰島素類似物活性藥物成分（API）和注射劑的研究、開發、生產和銷售，市值約為 425.5 億人民幣。</p>
</div><p><strong>Operations:</strong> Gan &amp; Lee Pharmaceuticals generates revenue primarily from the development, production, and sales of insulin and related products, amounting to CN¥3.85 billion. The company's operations focus on the biopharmaceutical sector within China.</p>
<div class="lb-trans"><p><strong>運營：</strong> 甘李藥業的收入主要來自胰島素及相關產品的開發、生產和銷售，金額為 38.5 億人民幣。該公司的運營專注於中國的生物製藥領域。</p>
</div><p>Gan &amp; Lee Pharmaceuticals, amidst a robust Asian tech landscape, is making significant strides with its innovative diabetes treatments. The company recently announced a licensing agreement with Lupin for Bofanglutide, potentially the first fortnightly GLP-1 receptor agonist, poised to transform obesity and diabetes management. This follows their insulin glargine's endorsement by the EMA as biosimilar to Lantus®, underscoring Gan &amp; Lee's commitment to expanding its global footprint in chronic disease care. With an impressive 35.8% increase in revenue year-over-year and earnings up by 61.3%, Gan &amp; Lee not only outpaces regional growth rates but also solidifies its role in shaping future healthcare solutions.</p>
<div class="lb-trans"><p>在強勁的亞洲科技環境中，甘李藥業在創新糖尿病治療方面取得了顯著進展。公司最近宣佈與 Lupin 簽署許可協議，推出 Bofanglutide，可能成為首個每兩週一次的 GLP-1 受體激動劑，有望改變肥胖和糖尿病管理。這一消息緊隨其胰島素甘精胰島素獲得 EMA 的生物類似藥認證，突顯了甘李藥業在慢性病護理領域擴展全球足跡的承諾。甘李藥業的收入同比增長 35.8%，盈利增長 61.3%，不僅超越了區域增長率，還鞏固了其在未來醫療解決方案中的角色。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Gan &amp; Lee Pharmaceuticals.</li>
<li>Review our historical performance report to gain insights into Gan &amp; Lee Pharmaceuticals''s past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解甘李藥業的完整分析健康報告。</li>
<li>查看我們的歷史業績報告，以獲取甘李藥業的過去表現洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/revenue-and-expenses-breakdown"/></p>
<p>SHSE:603087 Revenue and Expenses Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 SHSE:603087 收入和支出明細</p>
</div><h2>Accton Technology (TWSE:2345)</h2>
<div class="lb-trans"><h2>迅博科技 (TWSE:2345)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Accton Technology Corporation is engaged in the development, manufacturing, and sale of computer network systems and wireless LAN hardware and software products across Taiwan, the United States, the Asian-Pacific region, Europe, and other international markets with a market capitalization of NT$673.48 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 迅博科技股份有限公司從事計算機網絡系統及無線局域網硬件和軟件產品的開發、製造和銷售，業務覆蓋台灣、美國、亞太地區、歐洲及其他國際市場，市值為 6734.8 億新台幣。</p>
</div><p><strong>Operations:</strong> The primary revenue stream for Accton Technology comes from its computer network segment, generating NT$215.27 billion. The company operates across multiple regions, including Taiwan, the United States, and Europe.</p>
<div class="lb-trans"><p><strong>運營：</strong> 迅博科技的主要收入來源於其計算機網絡部門，收入為 2152.7 億新台幣。該公司在台灣、美國和歐洲等多個地區運營。</p>
</div><p>Accton Technology's recent strategic alliance with Edgecore Networks, 1Finity, and Liqid to develop a cutting-edge datacenter solution underscores its innovative edge in Asia's tech sector. This collaboration aims to enhance long-distance photonic network connectivity, crucial for modern datacenters requiring high transmission rates and low latency. Financially, Accton has shown robust growth with third-quarter revenue soaring to TWD 72.95 billion from TWD 28.19 billion year-over-year, while net income tripled to TWD 7.83 billion. These figures reflect a significant annualized revenue growth of 24.1% and earnings growth of 24.9%, positioning Accton well for future expansions in high-demand tech segments.</p>
<div class="lb-trans"><p>Accton Technology 最近與 Edgecore Networks、1Finity 和 Liqid 建立的戰略聯盟，旨在開發尖端的數據中心解決方案，突顯了其在亞洲科技領域的創新優勢。此次合作旨在增強長距離光子網絡連接，這對現代數據中心的高傳輸速率和低延遲至關重要。在財務方面，Accton 的第三季度收入從去年同期的 281.9 億新台幣飆升至 729.5 億新台幣，淨收入則增長至 78.3 億新台幣，增長了三倍。這些數據反映出年化收入增長率為 24.1%，盈利增長率為 24.9%，使 Accton 在高需求科技領域的未來擴展中處於良好位置。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Accton Technology.</li>
<li>Learn about Accton Technology's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Accton Technology 的動態。</li>
<li>瞭解 Accton Technology 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a35f34df-42b2-4cae-940c-cc2a6dd214f4/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/a35f34df-42b2-4cae-940c-cc2a6dd214f4/chart/revenue-and-expenses-breakdown"/></p>
<p>TWSE:2345 Revenue and Expenses Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>TWSE:2345 截至 2026 年 1 月的收入和支出明細</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Click through to start exploring the rest of the 183 Asian High Growth Tech and AI Stocks now.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊瀏覽其餘 183 家亞洲高增長科技和人工智能股票。</li>
<li>擁有這些公司的股份？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>免費使用 Simply Wall St 的應用程序簡化您的投資策略，並受益於對全球各地股票的廣泛研究。</li>
</ul>
</div><h2>Curious About Other Options?</h2>
<div class="lb-trans"><h2>對其他選擇感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過分析師和管理層的樂觀展望，為您的投資組合注入強勁增長潛力的公司。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

High Growth Tech Stocks in Asia to Watch January 2026

- 2026 年，亞洲市場動能各異，南韓出口創紀錄。
- 中國製造業復甦，技術增長潛力被看好。
- 重點公司包括依度科技和甘李藥業，均顯示出強勁增長趨勢。

2026 年 1 月值得關注的亞洲高增長科技股票